Phortas at ATMP Scientific Symposium
We are excited to share that Dr. Darius-Jean Namdjou, our Director, Senior Regulatory Lead at Phortas, recently participated in the...
Insights from the EMA Big Data Steering Group Workshop
We are thrilled to share that Jasmina Savic, our Managing Director at Phortas, recently participated in the European Medicines Agency...
Phortas Joins EU-X-CT Initiative: Pioneering Cross-Border Clinical Trials
Phortas has joined EU-X-CT: An initiative that seeks to enable and facilitate cross-border access to clinical trials for patients in...
Canada to potentially join parallel Scientific Advice with EMA and FDA for Complex Generics
Three years ago The FDA and the European Medicines Agency (EMA) have initiated a pilot program aimed at offering parallel scientific...
Phortas Members to Present at RAPS Euro Convergence 2024 in Berlin
We are delighted to announce that our two senior Phortas members will be presenting at RAPS Euro Convergence, scheduled from 06-08 May...
Phortas is Thrilled to Announce Our Participation at BioSpain 2023!
At Phortas, we are excited to share some remarkable news with you - we will be attending BioSpain 2023, one of Europe's premier...
Regulatory Pathways in the EU - overview
Prior to initiating a drug development program there are certain questions and considerations that should be answered with the main aim...
Future Trends in Healthcare
Intro The pharmaceutical industry has experienced significant growth during the past two decades, and pharma revenues worldwide totalled...
What to keep in mind as a developer of Drugs for Rare Diseases?
The definition of rare disease varies across countries and jurisdictions, but it usually takes into account disease prevalence, severity...
Best practices for development of pediatric medicines in the EU
What became evident with the introduction of the Paediatric Investigation Plan (PIP) procedure in Europe is that Regulatory Experts need...